Wire · opportunities
SK bioscience Advances Development of Next-Generation Infectious Disease Prevention ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 August 2026 · Fusion42 review
SK bioscience submitted a Clinical Trial Application to South Africa for a global Phase 1b trial of its RSV preventive antibody candidate, RSM01, targeting infants aged 2 weeks to 8 months to evaluate safety and pharmacokinetics. This move expands SK bioscience's infectious disease prevention portfolio from vaccines into antibody-based preventive technologies, supported by global partnerships including Gates MRI.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 14 Aug 2026 and 17 Aug 2026.
◆ ◆ The Wire takeaway
You can now enter infectious disease prevention beyond vaccines with antibody tech tested in infants. SK bioscience’s move shows partners want rapid clinical advances in antibody protection for babies worldwide.
◆ Coverage
2 sources · first reported 14 Aug 2026 · latest 17 Aug 2026
◆ Related on Wire
◆ Topics